Oral contraceptives, menopausal hormone therapy use and risk of B-cell non-Hodgkin lymphoma in the California Teachers Study

International Journal of Cancer

Volumn 129, Issue 4, 2011, Pages 974-982

  Lu, Yani ^a   Wang, Sophia S ^a   Sullivan Halley, Jane ^a   Chang, Ellen T ^b   Clarke, Christina A ^b   Henderson, Katherine D ^a   Ma, Huiyan ^a   Duan, Lei ^a   Lacey Jr , James V ^a   Deapen, Dennis ^c   Bernstein, Leslie ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

bilateral oophorectomy; hysterectomy; menopausal hormonal therapy; non Hodgkin lymphoma; oral contraceptives

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; B CELL LYMPHOMA; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG FORMULATION; FEMALE; FOLLICULAR LYMPHOMA; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENOPAUSE; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; CALIFORNIA; COHORT STUDIES; CONTRACEPTIVES, ORAL; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MENOPAUSE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 79959719806     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25730     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS,. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107: 265-76. (Pubitemid 43053551)
3. Jungers P, Dougados M, Pelissier C, Kuttenn F, Tron F, Lesavre P, Bach JF,. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 618-23. (Pubitemid 12078974)
4. Forsberg JG,. Short-term and long-term effects of estrogen on lymphoid tissues and lymphoid cells with some remarks on the significance for carcinogenesis. Arch Toxicol 1984; 55: 79-90. (Pubitemid 14081106)
5. Giltay EJ, Fonk JC, von Blomberg BM, Drexhage HA, Schalkwijk C, Gooren LJ,. In vivo effects of sex steroids on lymphocyte responsiveness and immunoglobulin levels in humans. J Clin Endocrinol Metab 2000; 85: 1648-57. (Pubitemid 32289513)
6. Kincade PW, Medina KL, Payne KJ, Rossi MI, Tudor KS, Yamashita Y, Kouro T,. Early B-lymphocyte precursors and their regulation by sex steroids. Immunol Rev 2000; 175: 128-37. (Pubitemid 30427163)
7. Bernstein L, Ross RK,. Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Res 1992; 52: 5510s-5515s.
8. Cerhan JR, Wallace RB, Folsom AR, Potter JD, Sellers TA, Zheng W, Lutz CT,. Medical history risk factors for non-Hodgkin's lymphoma in older women. J Natl Cancer Inst 1997; 89: 314-18. (Pubitemid 27085894)
9. Nelson RA, Levine AM, Bernstein L,. Reproductive factors and risk of intermediate- or high-grade B-Cell non-Hodgkin's lymphoma in women. J Clin Oncol 2001; 19: 1381-7. (Pubitemid 32202544)
10. Cerhan JR, Habermann TM, Vachon CM, Putnam SD, Zheng W, Potter JD, Folsom AR,. Menstrual and reproductive factors and risk of non-Hodgkin lymphoma: the Iowa women's health study (United States). Cancer Causes Control 2002; 13: 131-6. (Pubitemid 34229678)
11. Cerhan JR, Vachon CM, Habermann TM, Ansell SM, Witzig TE, Kurtin PJ, Janney CA, Zheng W, Potter JD, Sellers TA, Folsom AR,. Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev 2002; 11: 1466-71. (Pubitemid 35340386)
12. Beiderbeck AB, Holly EA, Sturkenboom MC, Coebergh JW, Stricker BH, Leufkens HG,. No increased risk of non-Hodgkin's lymphoma with steroids, estrogens and psychotropics (Netherlands). Cancer Causes Control 2003; 14: 639-44. (Pubitemid 37211120)
13. Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La Vecchia C,. Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 2003; 105: 408-12. (Pubitemid 36575452)
14. Altieri A, Gallus S, Franceschi S, Fernandez E, Talamini R, La Vecchia C,. Hormone replacement therapy and risk of lymphomas and myelomas. Eur J Cancer Prev 2004; 13: 349-51. (Pubitemid 39096089)
15. Zhang Y, Holford TR, Leaderer B, Boyle P, Zahm SH, Zhang B, Zou K, Morton LM, Owens PH, Flynn S, Tallini G, Zheng T,. Menstrual and reproductive factors and risk of non-Hodgkin's lymphoma among Connecticut women. Am J Epidemiol 2004; 160: 766-73. (Pubitemid 39362214)
16. Zhang Y, Holford TR, Leaderer B, Zahm SH, Boyle P, Morton LM, Zhang B, Zou K, Flynn S, Tallini G, Owens PH, Zheng T,. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 2004; 15: 419-28. (Pubitemid 38988028)
17. Skibola CF, Bracci PM, Paynter RA, Forrest MS, Agana L, Woodage T, Guegler K, Smith MT, Holly EA,. Polymorphisms and haplotypes in the cytochrome P450 17A1, prolactin, and catechol-O-methyltransferase genes and non-Hodgkin lymphoma risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 2391-401. (Pubitemid 41437842)
18. Norgaard M, Poulsen AH, Pedersen L, Gregersen H, Friis S, Ewertz M, Johnsen HE, Sorensen HT,. Use of postmenopausal hormone replacement therapy and risk of non-Hodgkin's lymphoma: a Danish population-based cohort study. Br J Cancer 2006; 94: 1339-41.
19. Lee JS, Bracci PM, Holly EA,. Non-Hodgkin lymphoma in women: reproductive factors and exogenous hormone use. Am J Epidemiol 2008; 168: 278-88. (Pubitemid 352019776)
20. Morton LM, Wang SS, Richesson DA, Schatzkin A, Hollenbeck AR, Lacey JV, Jr,. Reproductive factors, exogenous hormone use and risk of lymphoid neoplasms among women in the National Institutes of Health-AARP Diet and Health Study Cohort. Int J Cancer 2009; 124: 2737-43.
21. Stefanick ML,. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 2005; 118 (Suppl 12B): 64-73.
22. Smith DC, Prentice R, Thompson DJ, Herrmann WL,. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975; 293: 1164-7.
23. Ziel HK, Finkle WD,. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975; 293: 1167-70.
24. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J,. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33. (Pubitemid 34761611)
25. Bernstein L,. Combined hormone therapy at menopause and breast cancer: a warning-short-term use increases risk. J Clin Oncol 2009; 27: 5116-19.
26. Jaffe ES, Harris NL, Stein H, Vardiman J, eds. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2001.
27. Bernstein L, Allen M, Anton-Culver H, Deapen D, Horn-Ross PL, Peel D, Pinder R, Reynolds P, Sullivan-Halley J, West D, Wright W, Ziogas A, et al. High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control 2002; 13: 625-35. (Pubitemid 35001770)
28. World Health Organization. ICD-O: International Classification of Diseases for Oncology, 3rd edn. Geneva: World Health Organization, 2000.
29. Reynolds P, Hurley S, Goldberg DE, Anton-Culver H, Bernstein L, Deapen D, Horn-Ross PL, Peel D, Pinder R, Ross RK, West D, Wright WE, et al. Regional variations in breast cancer among California teachers. Epidemiology 2004; 15: 746-54. (Pubitemid 40416892)